Albany, New York, Feb 05, 2018: The human respiratory syncytial virus, also known as (RSV) causes infection in respiratory tract that includes breathing passage and lungs. This virus is the key cause to infect lower respiratory system, increasing the hospital visits especially in infants and children of around 2 years of age. According to the U.S. Centre for Disease Control and Prevention (CDC), respiratory syncytial virus is the most common reason behind pneumonia or bronchiolitis among young children in the United States. If figures are to be trusted, every year near about 75,000 to 125,000 children get hospitalized due to the infection caused by this virus. This infection is known to be contagious, such that it spreads through touch, kiss, or a hand shake with the person suffering from it. It can also spread through indirect contact such as coughing, sneezing, or blows of the patient. Some of the most common symptoms caused due to of respiratory syncytial virus are runny nose, sore throat, light headache, and cough. Polymerase chain reaction assay test is one of the several test carried for the diagnosis of the disease.
Rising number of children suffering from pneumonia, goes about as one of the main factor to boost the development of RSV diagnostic testing market. As indicated by the information specified by World Health Organization (WHO), in year 2010, around 1.1 million individuals in the United States were admitted because of suffering from pneumonia and almost 50,000 people passed away due to this ailment. Apart this, the rising population, crowded places, along with unhygienic surroundings – unhygienic eating places and dirty premises for examples, are likely to increase the odds of RSV contamination. This develops an urgent need and demand for effective and efficient RSV diagnostic tests. In any case, increased number of pathogens that are anticipated to cause side effects of respiratory sickness and absence of accessibility of particular treatment choices to check this disease may hamper the development of this market.
On the basis of diagnostic technology, the global respiratory syncytial virus diagnostic testing market is divided into molecular diagnostics, monoclonal antibodies, diagnostic imaging, gel microdroplets, flow cytometry, immunoassays, chromatography, and so on. As per the end users the market is segmented as hospitals, nursing homes, physician offices or group practices, or commercial laboratories. Based on geographical regions the market is broadly segmented into Asia Pacific, North America, Europe, and Rest of the World. Europe and North America took over the global RSV diagnostic testing market because of increase in the number of people battling eith respiratory syncytial virus. As indicated by the U.S. CDC, around 50,000 people have died because of pneumonia in the United States in the year 2012. Apart from this, Asia-Pacific nations, for example, China and India, South East Asian nations are the potential regions for worldwide RSV diagnostic testing market to flourish owing to increased prevalence of these infections especially bronchitis and pneumonia, in these regions and rise in healthcare awareness.
Among many, some of the major players in this industry are Beckman Coulter, Abbott Laboratories, Ortho-Clinical Diagnostics, Thermo Fisher Scientific F. Hoffman-La Roche, Ltd., bioMerieux, Bio-Rad Laboratories, Inc., Novartis Diagnostics, DiaSorin S.p.A , and Becton Dickson Organization among others.
Request to View Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2065